TABLE 1

NMDAR1 antisense treatment attenuates NMDA-induced nociceptive behaviors For days 1 to 5, treatment was twice a day (9:00 AM and 5:00 PM) and consisted of the i.t. administration of 5 μ l of saline, 30 nM NMDAR1 antisense, or 30 nM mismatch ODN. The ODN treatment was discontinued after testing on day 6. ED₅₀ values for NMDA-induced nociceptive behaviors with the 95% CI were determined on days 6 and 13 via a cumulative dose-response assessment.